Efficacy Over Time of LHRH Analogs in the Treatment of PCa—A Prospective Analysis Using Serum Testosterone to Determine Dosing Intervals

Published:December 24, 2008DOI:


      To examine the duration of serum testosterone and prostate-specific antigen suppression after each dose of a 4-month depot leuprolide acetate for 18 months and to assess the potential for using serum testosterone as a guide for redosing the luteinizing hormone-releasing hormone analogs instead of using fixed dosing intervals. Luteinizing hormone-releasing hormone analogs are well established for the treatment of prostate cancer (PCa). However, many open questions remain regarding the optimal dosing.


      Thirteen patients with PCa were enrolled in a longitudinal study. Serum testosterone levels were obtained at baseline and then monthly beginning 4 months after the first injection and every 2 months after the subsequent injections, for a total of 18 months. The median number of days from injection to the first serum testosterone level ≥50 ng/dL was estimated using the Kaplan-Meier product-limit method.


      The median duration of effect was 159, 189, and 163 days for the first, second, and third treatment cycle, respectively. The prostate-specific antigen values from entry to completion decreased in all subjects. The total number of injections was reduced in all but one subject who completed the 18-month trial. One patient developed hormone-refractory PCa.


      Serum testosterone measurement might be a useful method for redosing luteinizing hormone-releasing hormone analogs. Using testosterone levels to determine the time of reinjection has a significant economic impact. Monitoring serum testosterone not only helps to identify patients who fail to achieve testosterone suppression but also provides close monitoring for the potential development of hormone-refractory PCa.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Oefelein M.G.
        Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant dosing study considerations.
        J Urol. 1998; 160: 1685-1688
        • Oefelein M.G.
        Serum testosterone-based luteinizing hormone-releasing hormone agonist redoing schedule for chronic androgen ablation: a phase I assessment.
        Urology. 1999; 54: 649-699
        • Oefelein M.G.
        Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing agonists in patients with prostate cancer.
        J Urol. 2003; 169: 251-255
        • Pathak A.S.
        • Pacificar J.S.
        • Shapiro C.E.
        • et al.
        Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
        J Urol. 2007; 177: 2132-2135
        • Nejat R.J.
        • Rashid H.H.
        • Bagiella E.
        • et al.
        A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
        J Urol. 2000; 164: 1891-1894
        • Walsh P.C.
        Physiological basis for hormonal therapy in carcinoma of the prostate.
        Urol Clin North Am. 1975; 2: 25-28
        • Bayoumi A.M.
        Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
        J Natl Cancer Inst. 2000; 92: 1731-1739
        • Calais Da Silva F.M.
        • Calais Da Silva F.
        • Bono A.
        • et al.
        Phase III intermittent MAB vs continuous MAB.
        J Clin Oncol. 2006; 24: 220-227
        • Oefelein M.G.
        • Cornum R.
        Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
        J Urol. 2000; 164: 726-729

      Linked Article